Achillion stock plunges as FDA maintains clinical hold on hep C drug

(Reuters) - Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration decided not to lift a clinical hold it had placed on the firm's hepatitis C drug, sovaprevir, leaving an uncertain fate for the company's most promising drug. The news caused Achillion's shares to plunge 45 percent in after-market trade on Friday. The FDA asked the company to halt development of sovaprevir in June, after detecting elevated liver enzymes, an indication of liver damage, in multiple patients who were given the drug in a clinical study. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/achillion-stock-plunges-fda-maintains-clinical-hold-hep-004859500--finance.html